Pancreatic Cancer Research

ResearcherRenovoRx, Inc. (United States)Active in the last 2 years

Ramtin Agah

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-6862-0289; OpenAlex author ID A5081920546. Sources: ClinicalTrials.gov.

Their work

Papers
3 (first author 0, last author 3)
Trials
1
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2015: 1 trial · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

  1. Trans-arterial gemcitabine micro perfusion of locally advanced pancreatic cancer enabled by coil plus glue embolization of a pancreaticoduodenal branch. Last author DOI 10.1016/j.radcr.2026.04.043↗
  2. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2. Last author DOI 10.1093/oncolo/oyae178↗
  3. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1089/pancan.2017.0011↗

Trials 1

  1. Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter Study director NCT02591082↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Béla Kis · 1 shared paper, 2026 · strength 0.36
  2. Alexander S. Rosemurgy · 2 shared papers, 2017–2024 · strength 0.26
  3. Hassan A. Hatoum · 1 shared paper, 2024 · strength 0.18
  4. Peter Muscarella Md · 1 shared paper, 2024 · strength 0.18
  5. Barish H. Edil · 1 shared paper, 2024 · strength 0.18
  6. Emmanuel E. Zervos · 1 shared paper, 2024 · strength 0.18
  7. Sharona B Ross · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.